RxDoctor Payments Data

Robert Novick, MD

Cardiovascular Disease · Casper, WYNPI 1538106554

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,308 of the $3,546 with a category attached, or 65.1%. Boston Scientific accounts for 61.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $1,200 and has fallen 63.2% since, to $441 in 2025.

$3,546in general payments, 2019–2025

Across 89 payments — averaging $39.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Artivion, Inc.$527
  • Shockwave Medical, Inc$201
  • Impulse Dynamics (USA) Inc.$193
  • Novartis$144
  • AstraZeneca$112
  • plus $188 from 6 others

What the payments were for

  • Travel & lodging$1,23835%
  • Food & beverage$2,30865%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,546 in reported general payments places this provider in the 85th percentile of 22 cardiovascular disease providers in Wyoming.

See all cardiovascular disease providers in Wyoming

Medicare billing

Part B allowed, 2024
$83,227
Medicare patients
163
Services billed
429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban148$132,543
EntrestoSacubitril/Valsartan49$37,334
Flecainide Acetate26$1,278
Metoprolol Succinate76$951
Atorvastatin Calcium110$950
Rosuvastatin Calcium40$894
Potassium Chloride38$816
Midodrine Hcl17$640
Losartan Potassium65$595
Torsemide25$502
Metoprolol Tartrate110$480
Warfarin Sodium30$457
Lisinopril66$444
Amlodipine Besylate90$436
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$144$37,33449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 22 cardiovascular disease providers in Wyoming.

Other cardiovascular disease in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →